Test Price
2,800 AED✅ Home Collection Available
AGRN Gene Congenital Myasthenic Syndrome (CMS) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited NGS processing and ACMG/AMP variant interpretation.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic post‑test counselling by a DHA‑licensed genetic counsellor to help interpret AGRN variant reports.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 — most major UAE insurers accepted.
Test Overview & Methodology
The AGRN Gene Congenital Myasthenic Syndrome Genetic Test is a highly sensitive next‑generation sequencing assay that screens the entire coding region and splice junctions of the AGRN gene for pathogenic variants linked to post‑synaptic congenital myasthenic syndrome.
| Feature | Our Test (DHA‑Approved) | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity; full gene NGS with CNV calling | Single‑gene Sanger sequencing (misses exonic deletions) |
| Methodology | SureSelect Human All Exon V8 + NovaSeq 6000; ACMG/AMP variant interpretation | Targeted panel or single‑site analysis |
| Speed | 3–4 weeks from sample receipt | Often 6–8 weeks |
| Home Collection | VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection | Limited or self‑arranged |
Physician Insight & Safety Protocols
“A positive AGRN mutation confirms the diagnosis but must be placed in the full clinical and electrophysiological context. Negative results do not exclude congenital myasthenic syndrome; further genetic and metabolic work‑up is often indicated.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Warning
⚠ Medication Safety Warning
Do not discontinue prescribed anticholinesterase agents, immunosuppressants, or respiratory support without prior consultation with your treating physician.
Exclusion Criteria & Who Should Not Take This Test
Exclusion Criteria
- Recent blood transfusion or bone marrow transplant within the last 7 days.
- Acute severe infection or haemodynamic instability.
- Known maternal cell contamination in neonatal samples (maternal DNA may confound results).
- Inability to provide informed consent (minors require consent of both parents as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
Emergency Red Flags – Seek Immediate Medical Help
- Sudden worsening of muscle weakness, difficulty swallowing, or breathing distress.
- Choking, aspiration, or dropping oxygen saturation below 92%.
- Any acute deterioration in a child already suspected of congenital myasthenic syndrome.
Patient FAQ & Clinical Guidance
1. How accurate is this genetic test for diagnosing congenital myasthenic syndrome?
The NGS‑based comprehensive AGRN gene analysis provides diagnostic confirmation with >99.9% sensitivity for known pathogenic variants in clinically suggestive cases.
2. Can my child have this test without fasting or stopping medication?
No fasting is required for a DNA blood draw, and you must never stop prescribed medication without your doctor’s explicit approval.
3. What if the test is negative but my child still has symptoms?
A negative AGRN result does not rule out other genetic or autoimmune forms of myasthenia, and your neurologist may recommend a broader CMS gene panel and neurophysiological studies.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is processed exclusively on Dubai‑based servers and shared only with the ordering physician or authorised healthcare proxy.
Clinical & Logistical Metadata
| Test Name | AGRN Gene Congenital Myasthenic Syndrome (CMS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA) |
| Methodology Used | Next Generation Sequencing (SureSelect Human All Exon V8 + NovaSeq 6000); ACMG/AMP variant interpretation |
| ICD-10-CM Code | G70.2, Z15.89, Z13.71 |
| LOINC Code | 101502-6 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians